S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: US futures mostly higher ahead of debt ceiling vote, oil falls again
New "Mined in America" Lithium Opportunities? (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush
New "Mined in America" Lithium Opportunities? (Ad)
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: US futures mostly higher ahead of debt ceiling vote, oil falls again
New "Mined in America" Lithium Opportunities? (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush
New "Mined in America" Lithium Opportunities? (Ad)
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: US futures mostly higher ahead of debt ceiling vote, oil falls again
New "Mined in America" Lithium Opportunities? (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush
New "Mined in America" Lithium Opportunities? (Ad)
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: US futures mostly higher ahead of debt ceiling vote, oil falls again
New "Mined in America" Lithium Opportunities? (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush
New "Mined in America" Lithium Opportunities? (Ad)
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
NASDAQ:EDIT

Editas Medicine (EDIT) Stock Forecast, Price & News

$9.10
+0.02 (+0.22%)
(As of 05/26/2023 08:46 PM ET)
Compare
Today's Range
$8.94
$9.21
50-Day Range
$6.36
$10.28
52-Week Range
$6.33
$19.97
Volume
1.06 million shs
Average Volume
2.00 million shs
Market Capitalization
$627.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.86

Editas Medicine MarketRank™ Forecast

Analyst Rating
Hold
2.31 Rating Score
Upside/​Downside
74.3% Upside
$15.86 Price Target
Short Interest
Bearish
29.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.56
Upright™ Environmental Score
News Sentiment
0.76mentions of Editas Medicine in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$19,777 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.04) to ($3.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

755th out of 1,009 stocks

Biological Products, Except Diagnostic Industry

119th out of 167 stocks


EDIT stock logo

About Editas Medicine (NASDAQ:EDIT) Stock

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

EDIT Stock News Headlines

The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
Editas Medicine (NASDAQ:EDIT) Shares Up 7.8%
Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
Editas Medicine (NASDAQ:EDIT) Upgraded at StockNews.com
6 Analysts Have This to Say About Editas Medicine
Editas Medicine (EDIT) Gets a Hold from Credit Suisse
See More Headlines
Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

EDIT Company Calendar

Last Earnings
5/05/2023
Today
5/29/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EDIT
Fax
N/A
Employees
264
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.86
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+74.3%
Consensus Rating
Hold
Rating Score (0-4)
2.31
Research Coverage
13 Analysts

Profitability

Net Income
$-220,430,000.00
Net Margins
-960.70%
Pretax Margin
-960.70%

Debt

Sales & Book Value

Annual Sales
$19.71 million
Book Value
$5.25 per share

Miscellaneous

Free Float
67,478,000
Market Cap
$627.90 million
Optionable
Optionable
Beta
1.86

Key Executives

  • Gilmore O’Neill
    President, Chief Executive Officer & Director
  • Harry R. Gill
    Senior Vice President-Operations
  • Erick J. Lucera
    Chief Financial Officer & Executive Vice President
  • Bruce E. EatonBruce E. Eaton
    Executive VP, Chief Business & Technology Officer
  • Mei Baisong
    Chief Medical Officer & Senior Vice President













EDIT Stock - Frequently Asked Questions

Should I buy or sell Editas Medicine stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View EDIT analyst ratings
or view top-rated stocks.

What is Editas Medicine's stock price forecast for 2023?

13 brokerages have issued 1-year price targets for Editas Medicine's stock. Their EDIT share price forecasts range from $7.00 to $35.00. On average, they expect the company's stock price to reach $15.86 in the next twelve months. This suggests a possible upside of 74.3% from the stock's current price.
View analysts price targets for EDIT
or view top-rated stocks among Wall Street analysts.

How have EDIT shares performed in 2023?

Editas Medicine's stock was trading at $8.87 at the beginning of the year. Since then, EDIT shares have increased by 2.6% and is now trading at $9.10.
View the best growth stocks for 2023 here
.

Are investors shorting Editas Medicine?

Editas Medicine saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 20,230,000 shares, an increase of 7.3% from the April 30th total of 18,860,000 shares. Based on an average daily volume of 1,840,000 shares, the short-interest ratio is presently 11.0 days.
View Editas Medicine's Short Interest
.

When is Editas Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our EDIT earnings forecast
.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) posted its earnings results on Friday, May, 5th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.08. The firm had revenue of $9.90 million for the quarter, compared to analysts' expectations of $3.29 million. Editas Medicine had a negative trailing twelve-month return on equity of 56.20% and a negative net margin of 960.70%. The company's revenue for the quarter was up 45.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.74) EPS.

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (11.83%), BlackRock Inc. (10.75%), Dimensional Fund Advisors LP (2.34%), Geode Capital Management LLC (2.10%), JPMorgan Chase & Co. (1.64%) and Pictet Asset Management SA (1.53%). Insiders that own company stock include Bruce Eaton, Charles Albright, Cynthia Collins, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends
.

How do I buy shares of Editas Medicine?

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $9.10.

How much money does Editas Medicine make?

Editas Medicine (NASDAQ:EDIT) has a market capitalization of $627.90 million and generates $19.71 million in revenue each year. The company earns $-220,430,000.00 in net income (profit) each year or ($3.18) on an earnings per share basis.

How many employees does Editas Medicine have?

The company employs 264 workers across the globe.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for the company is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com.

This page (NASDAQ:EDIT) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -